Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2

<table>
<thead>
<tr>
<th>著者</th>
<th>田辺優子</th>
</tr>
</thead>
<tbody>
<tr>
<td>著者別表示</td>
<td></td>
</tr>
<tr>
<td>学位授与番号</td>
<td>博士論文本文番号</td>
</tr>
<tr>
<td>学位名</td>
<td>博士（医学）</td>
</tr>
<tr>
<td>学位授与年月日</td>
<td></td>
</tr>
</tbody>
</table>

doi: https://doi.org/10.1016/j.cyto.2016.02.008
Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2

Yuko Tasaki\textsuperscript{a}, Masaki Shimizu\textsuperscript{a,*}, Natsumi Inoue\textsuperscript{a}, Mao Mizuta\textsuperscript{a}, Yasuo Nakagishi\textsuperscript{b}, Taizo Wada\textsuperscript{a}, Akihiro Yachie\textsuperscript{a}

\textsuperscript{a}Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Japan

\textsuperscript{b}Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Japan

\textsuperscript{*}Corresponding author at: Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Japan.

E-mail address: shimizum@staff.kanazawa-u.ac.jp (M. Shimizu).

ARTICLE INFO

Article history:
Received 12 August 2015
Received in revised form 14 January 2016
Accepted 15 February 2016
Available online 22 February 2016

Keywords:
Systemic juvenile idiopathic arthritis
Macrophage activation syndrome
Angiopoietin 1
Angiopoietin 2
Endothelial function

ABSTRACT

To assess the role of angiopoietin (Ang)-1 and Ang-2 and to investigate the clinical significance of serum levels of them in systemic juvenile idiopathic arthritis (s-JIA)-associated macrophage activation syndrome (MAS), we determined these levels in 51 patients with s-JIA, 11 patients with polyarticular JIA (poly-JIA), 12 patients with virus associated hemophagocytic syndrome (VAHS), 12 patients with Kawasaki disease (KD), and 15 age-matched healthy controls (HC). The results were compared with clinical features of MAS. During the MAS phase, serum Ang-1 levels were significantly decreased compared with those during the active and inactive phases. Serum Ang-2/1 ratio were significantly elevated during the MAS phase, compared with those during the active and inactive phases. There was a rapid increase in the Ang-2/1 ratio at the onset of MAS. Serum Ang-1 and the Ang-2/1 ratio significantly correlated with measures of disease activity, including AST and LDH. Ang-2/1 dysregulation was also observed in patients with VAHS, whereas not observed in most cases of KD. The homeostasis of vascular endothelial function by Ang-1 and Ang-2 is disrupted in MAS. Serum Ang-1 levels and the Ang-2/1 ratio might represent promising indicators of disease activity for MAS.

1. Introduction

Systemic juvenile idiopathic arthritis (s-JIA) is a unique subtype of JIA, characterized by arthritis and other systemic features including spiking fever, salmon colored skin rash, hepatosplenomegaly, generalized lymphadenopathy, and polyserositis [1]. Recent studies have shown that s-JIA might be driven by innate proinflammatory cytokines. In particular, interleukin (IL)-1, IL-6, IL-18 play an important roles in the pathogenesis of s-JIA [2,3]. Furthermore, biological therapies that block these cytokines have dramatic effects in patients with s-JIA [4,5]. These findings support the hypothesis that s-JIA is an autoinflammatory condition.

Macrophage activation syndrome (MAS) is a potentially fatal condition of s-JIA, characterized by fever, cytopenias, hepatosplenomegaly, lymphadenopathy, liver dysfunction, coagulopathy, and central nervous system dysfunction [6]. MAS is a secondary form of hemophagocytic lymphohistiocytosis (HLH) and massive hypercytokinemia induced by excess activation of macrophages and proliferation of T lymphocytes is closely associated with the development of MAS [6].

Vascular endothelial cells activated by inflammatory cytokines act as a procoagulant surface and contribute to intravascular coagulation of s-JIA [2]. Angiopoietins (Ang)-1 and -2 are key regulators of endothelial cell function [7,8]. In inflammatory conditions including sepsis and hemolytic uremic syndrome, the Ang-2/1 ratio increases because of decreased Ang-1, increased Ang-2 [9–12]. We speculated that dysregulation of the Ang-2/1 ratio is also present in s-JIA, and that the homeostasis of vascular endothelial function by Ang-1 and Ang-2 is disrupted in MAS.

To assess the role of Ang-1 and Ang-2 in endothelial damage in the pathogenesis of s-JIA and MAS, we measured serum Ang-1 and Ang-2 levels in patients with s-JIA. We compared them with the
Levels in patients with virus associated hemophagocytic syndrome (VAHS), a secondary form of HLH as well as MAS and Kawasaki disease (KD), a popular pediatric vasculitis which complicates the vascular endothelial damage. We determined the correlation between the levels of serum Ang-1 and Ang-2 levels, and the Ang-2/1 ratio with measures of disease activity and severity in order to clarify the clinical significance of these levels as indicators of disease activity for MAS.

2. Materials and methods

2.1. Patients and samples

Serum samples were obtained from 51 patients with s-JIA, 11 patients with polyarticular JIA (poly-JIA), 12 patients with Kawasaki disease (KD), and 15 age-matched healthy controls (HC) (mean age s-JIA: 7.9 ± 5.4 years, mean age poly-JIA: 11.8 ± 5.0 years, mean age KD: 1.5 ± 1.4 years, mean age HC: 9.3 ± 7.8 years). Plasma samples were obtained from 12 patients with virus associated hemophagocytic syndrome (VAHS) (mean age VAHS: 5.0 ± 4.0 years). Eleven patients with s-JIA had MAS, and seven of these had already developed MAS by the time they were referred to us at the onset of s-JIA. Four patients with s-JIA developed MAS during the active phase after beginning immunosuppressive therapy with steroids and/or tocilizumab. Samples from these four patients were obtained during the active and inactive phases of s-JIA. The clinical characteristics of the patients with active s-JIA are shown in Supplementary Table 1. Furthermore, samples were obtained from 12 patients with s-JIA who had MAS during the active phase after beginning immunosuppressive therapy with steroids and/or tocilizumab. Samples from these four patients were obtained during the active and inactive phases of s-JIA. The clinical characteristics of the patients with MAS are shown in Supplementary Table 1. Furthermore, samples from 16 patients with s-JIA were obtained during the active and inactive phases of s-JIA. The diagnoses of s-JIA and poly-JIA were based on the criteria of the International League of Associations for Rheumatology [13]. MAS was diagnosed based on the guidelines proposed by Ravelli et al [14]. The criteria for the active phase of s-JIA were defined as follows: active arthritis, fever, salmon colored rash, hepatosplenomegaly, generalized lymphadenopathy, polyserositis, increased erythrocyte sedimentation rate, and increased serum C-reactive protein (CRP) level. The criteria for the inactive phase of s-JIA on medication were as follows: the absence of clinical symptoms observed in the active phase of s-JIA, normal erythrocyte sedimentation rate, and normal serum CRP level. The diagnosis of VAHS was made according to established HLH diagnostic criteria [15]. The diagnosis of KD was based on the classic clinical criteria [16].

<table>
<thead>
<tr>
<th>Table 1 Clinical characteristics of patients with active systemic juvenile idiopathic arthritis.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>44</td>
</tr>
<tr>
<td>Sex</td>
<td>Male 20 female 24</td>
</tr>
<tr>
<td>Age (years)</td>
<td>8.4 ± 5.5</td>
</tr>
<tr>
<td>Disease duration (months)</td>
<td>11.2 ± 39.0</td>
</tr>
<tr>
<td>Laboratory findings</td>
<td></td>
</tr>
<tr>
<td>CRP (mg/dl) (n = 43)</td>
<td>10.1 ± 7.1</td>
</tr>
<tr>
<td>AST (IU/L) (n = 48)</td>
<td>47.5 ± 33.1</td>
</tr>
<tr>
<td>LDH (IU/L) (n = 48)</td>
<td>367.1 ± 150.2</td>
</tr>
<tr>
<td>Ferritin (ng/ml) (n = 48)</td>
<td>1669.4 ± 2926.7</td>
</tr>
<tr>
<td>FDP-DD (n = 34)</td>
<td>6.1 ± 7.0</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>PSL (mg/kg/day) (n = 13)</td>
<td>0.77 ± 0.55</td>
</tr>
<tr>
<td>CyA (mg/kg/day) (n = 5)</td>
<td>2.7 ± 1.6</td>
</tr>
<tr>
<td>MTX (mg/m2/week) (n = 1)</td>
<td>10</td>
</tr>
<tr>
<td>TCZ (mg/kg/2 weeks) (n = 5)</td>
<td>8</td>
</tr>
</tbody>
</table>

Sera and plasma were separated from the cells, divided into aliquots, frozen, and stored at -80°C until use. This study was approved by the Institutional Review Board at Kanazawa University, and all specimens were used only after informed consent was obtained according to the Declaration of Helsinki.

2.2. Quantification of serum cytokines

Levels of Ang-1 and Ang-2 were evaluated using enzyme-linked immunosorbent assay (ELISA), according to the manufacturer’s instructions (RayBio Human Angiopoietin-1,-2 ELISA kit, RayBio-tech, Norcross, GA, USA). The levels of Ang-1 and Ang-2 could be measured equally well in plasma and serum samples.

2.3. Statistical analysis

Within-group comparisons were analyzed using the Mann-Whitney test or paired t-test. Correlations were analyzed using the Spearman rank correlation coefficient. Analyzed measures with p values <0.05 were considered to be statistically significant.

3. Results

3.1. Disruption of vascular endothelial homeostasis by Ang-1 and Ang-2 in s-JIA and MAS

The serum Ang-1 and Ang-2 levels were determined in patients with s-JIA, and compared with the levels in patients with poly-JIA, VAHS, KD and in HC. As shown in Fig. 1A, the MAS phase in patients with s-JIA, the serum Ang-1 levels were significantly decreased (41,583 ± 27,773 pg/ml) compared with those during the active (100,866 ± 42,949 pg/ml, p = 0.0001) and inactive phases (120,553 ± 33,076 pg/ml, p = 0.0001) in patients with s-JIA, and compared with those in patients with poly-JIA (101,850 ± 25,951 pg/ml, p = 0.01), in KD (114,517 ± 23,080 pg/ml, p = 0.001) and in HC (100,740 ± 31,718 pg/ml, p < 0.001). Serum Ang-1 levels in patients with VAHS were also significantly decreased (41,583 ± 27,773 pg/ml) compared with those during the active and inactive phases in patients with s-JIA, and compared with those in patients with poly-JIA in KD and in HC (100,740 ± 31,718 pg/ml, p < 0.001). As shown in Fig. 1B, during the MAS phase in patients with s-JIA, serum Ang-2 levels were significantly elevated (8750 ± 7488 pg/ml) compared with those during the active (5514 ± 5392 pg/ml, p < 0.05) and inactive phases (2836 ± 1341 pg/ml, p < 0.01) in patients with s-JIA, and compared with those in patients with poly-JIA (2631 ± 1554 pg/ml, p < 0.05), in VAHS (5225 ± 6784 pg/ml, p < 0.05), in KD (4191 ± 3704 pg/ml, p < 0.01) and in HC (2317 ± 1035 pg/ml, p < 0.001). As shown in Fig. 1C, during the MAS phase in patients with s-JIA, the Ang-2/1 ratio was significantly elevated (0.272 ± 0.254 pg/ml) compared with that during the active (0.066 ± 0.071 pg/ml, p < 0.001) and inactive phases (0.026 ± 0.012 pg/ml, p < 0.0001) in patients with s-JIA, and compared with those in patients with poly-JIA (0.028 ± 0.019 pg/ml, p < 0.001), in KD (0.036 ± 0.028 pg/ml, p < 0.0001) and in HC (0.023 ± 0.007 pg/ml, p < 0.0001). Furthermore, as shown in Fig. 1C, during the active phase, the Ang-2/1 ratio was significantly elevated compared with that during the inactive phase in patients with s-JIA (p < 0.01), and compared with that in patients with poly-JIA (p < 0.05) and in HC (p < 0.01) (Fig. 1C). However, the Ang-2/1 ratio during the active phase of s-JIA were significantly decreased compared with those in patients with VAHS (0.165 ± 0.196 pg/ml, p < 0.05).

Table 1 Clinical characteristics of patients with active systemic juvenile idiopathic arthritis.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/dl)</td>
<td>10.1 ± 7.1</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>47.5 ± 33.1</td>
</tr>
<tr>
<td>LDH (IU/L)</td>
<td>367.1 ± 150.2</td>
</tr>
<tr>
<td>Ferritin (ng/ml)</td>
<td>1669.4 ± 2926.7</td>
</tr>
<tr>
<td>FDP-DD (n = 34)</td>
<td>6.1 ± 7.0</td>
</tr>
</tbody>
</table>

**Notes:**
- CRP: C-reactive protein; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; FDP-DD: fibrin degradation product D-dimer; PSL: prednisolone; CyA: cyclosporine; MTX: methotrexate; TCZ: tocilizumab.
3.2. The time course of changes in serum Ang-1 levels and the Ang-2/1 ratio in four patients with MAS

To investigate the relevance of Ang-1 and Ang-2 in the pathogenesis of MAS, serum Ang-1 and Ang-2 levels were serially monitored in four cases of MAS (Fig. 2A–D). The serum Ang-1 levels profoundly and rapidly decreased as MAS developed. However, the Ang-2/1 ratio profoundly and rapidly increased as MAS developed. The Ang-2/1 ratio subsequently decreased after such manifestations disappeared with immunosuppressive therapy. As shown in Fig. 2A and D, in cases of uncontrolled disease activity, serum Ang-1 levels were decreased and the Ang-2/1 ratio was elevated.

3.3. Correlation between serum Ang-1 and Ang-2 levels and Ang-2/1 ratio and measures of disease activity in patients with s-JIA and MAS

Because serum CRP, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and ferritin levels are clinically used as indicators of disease activity in s-JIA, these levels were compared with the serum Ang-1 and Ang-2 levels and the Ang-2/1 ratio. Serum Ang-1 levels negatively correlated with AST, LDH, and ferritin (Fig. 3A–C). Serum Ang-2 levels positively correlated with AST and LDH (Fig. 3D and E). The Ang-2/1 ratio positively correlated with AST, LDH, and ferritin (Fig. 4A–C). Furthermore, levels of the plasma fibrin degradation product D-dimer (FDP-DD) are clinically used as indicators of coagulopathy. Therefore, FDP-DD concentrations were compared with serum Ang-1 and Ang-2 levels and the Ang-2/1 ratio. The Ang-2/1 ratio positively correlated with FDP-DD concentrations (Fig. 4D).

4. Discussion

Ang-1 and Ang-2 competitively bind to the endothelial Tie-2 receptor [7,8]. Ang-1 is constitutively produced by pericytes, smooth muscle cells and fibroblast. Ang-2 is produced by endothelial cells. In healthy individuals, Ang-2 expression is almost absent in the resting vasculature. Serum concentrations of Ang-1 exceed those of Ang-2 and Ang2/1 ratio is low. Ang-1 binds to the Tie-2 receptor and control vascular quiescence through the negative regulation of proinflammatory pathways [7,8]. In inflammatory conditions, Ang-2 expression is dramatically induced by various stresses. Ang-2 is released from endothelial cells and competes with Ang-1 for binding to the Tie-2 receptor. Consequently, Ang-2 triggers proinflammatory and prothrombotic pathways by activating endothelial cells.

Various stresses including hypoxia, inflammation, and high glucose concentrations induce Ang2/1 dysregulation [7,8]. Cytokines and growth factors including tumor necrosis factor (TNF)-α, vascular endothelial growth factor, and fibroblast growth factor promote destabilized angiogenesis by modulating angiopoietin expression [7,8]. Among the cytokines closely related to the pathogenesis of s-JIA, previous studies have shown that IL-1β downregulates Ang-1 expression [17]. Furthermore, IL-6 inhibits Ang-1 signaling by downregulating Ang-1 expression and upregulating Ang-2 expression [18,19].

In this study, we demonstrated that the Ang-2/1 ratio, which reflects a relative excess of Ang-2, was significantly elevated in the active phase of s-JIA. Furthermore, serum Ang-1 levels were significantly decreased in MAS, whereas the serum Ang-2 levels and the Ang-2/1 ratio were significantly elevated in MAS. These findings are consistent with the known biological roles of Ang-1.
and Ang-2, and their predicted impact on endothelial cell function in the pathogenesis of s-JIA and MAS. In agreement with these findings, endothelial cell dysfunction by Ang-2/1 dysregulation is present in children with s-JIA and represents the clinical manifestation of endothelial cell dysfunction. In the pathology of s-JIA, proinflammatory cytokines, such as IL-1β and IL-6, induce Ang2/1 dysregulation through downregulation of Ang-1 expression and upregulation of Ang-2 expression. Furthermore, the homeostasis of endothelial function by Ang-1 and Ang-2 is disrupted as MAS develops, inducing vascular endothelial cell damage and coagulopathy. Interestingly, Ang-2/1 dysregulation was also observed in patients with VAHS, a secondary form of HLH as well as MAS. In contrast, Ang-2/1 dysregulation was not observed in most cases of KD. From these findings, Ang-2/1 dysregulation is characteristic to the diseases with progressive endothelial dysfunction such as MAS and HLH.

In this study, the Ang-2/1 ratio profoundly and rapidly increased as MAS developed. Furthermore, the Ang-2/1 ratio decreased after such manifestations disappeared with corticosteroid and cyclosporine therapy. As shown in Fig. 1A and D, serum Ang-1 levels were decreased and the Ang-2/1 ratio was elevated in cases of uncontrolled disease activity. From these findings, the Ang-2/1 ratio may represent a promising indicator of disease activity for MAS.

In addition to the role of Ang-2/1 in the homeostasis of endothelial function, several lines of evidence have suggested that Ang-1 and Ang-2 play roles in the exacerbation of synovitis in patients with rheumatoid arthritis (RA) [18,20,21]. Ang-1, Ang-2, and Tie2, are expressed in RA synovial tissue [20,21]. In the synovial tissue of RA patients, Tie2 activation has been shown to be predominantly localized to macrophages [18]. Ang-1/2 has been shown to stimulate the activation of intracellular signaling pathways, and cooperate with TNF to induce macrophage IL-6 and macrophage inflammatory protein 1α production [21]. These findings indicate that the synovial macrophage is a primary target of Ang-signaling, promoting the proinflammatory activation of human macrophages. In animal models of RA, neutralization of Ang-2 was shown to significantly decrease disease severity, synovial inflammation, neo-vascularization, and joint destruction [21]. From these findings, Ang-1 and Ang-2 may play important roles in the development of arthritis in s-JIA and RA. Furthermore, direct targeting of Ang-2 may provide therapeutic benefit in the treatment of s-JIA-associated MAS.

The limitation of the present study was the small number of patients with s-JIA. Further larger studies may help to define the true diagnostic value of Ang-1 and Ang-2. However, despite this limitation, our results suggest that Ang-1 and Ang-2 play important roles in the complex network involved in the inflammation
of s-JIA and MAS. The homeostasis of endothelial function by Ang-1 and Ang-2 is disrupted in MAS. The Ang-2/1 ratio may represent a promising indicator of disease activity for MAS.

**Fig. 3.** Correlations between serum angiopoietin (Ang)-1 and Ang-2 levels and measures of disease activity. (A, Ang-1 and AST; B, Ang-1 and LDH; C, Ang-1 and ferritin; D, Ang-2 and AST; E, Ang-2 and LDH). AST, aspartate aminotransferase; LDH, lactate dehydrogenase.

**Fig. 4.** Correlations between angiopoietin 2/1 ratio and measures of disease activity. (A, AST; B, LDH; C, ferritin; D, FDP-DD). AST, aspartate aminotransferase; LDH, lactate dehydrogenase; FDP-DD, fibrin degradation product D-dimer.

**Financial disclosure**

The authors have no financial relationship to this article to disclose.

**Conflict of interest**

The authors have no conflicts of interest to disclose.

**Funding source**

No external funding was granted to this study.
Acknowledgment

We thank Harumi Matsukawa for technical assistance.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.cyto.2016.02.008.

References